InVirtuoLabs closes R&D agreement with Helsinn
InVirtuoLabs signed an R&D agreement with Helsinn to apply its generative chemistry platform, InVirtuoGEN, to design and optimize novel drug candidates. Helsinn will provide a proprietary library of validated hits to support hit-to-lead progression toward preclinical development. The partnership aims to accelerate lead identification and lower discovery costs and timelines.
Why it mattersHelsinn provided a proprietary validated-hit library, enabling InVirtuoLabs to accelerate hit-to-lead progression and shorten discovery timelines.